Hui An

Title: Hui An - Innovator in Pharmaceutical Technology

Introduction: Hui An is a talented inventor based in Shijiazhuang, China. She is currently associated with Cspc Zhongqi Pharmaceutical Technology Co., Ltd. Despite having no granted patents to her name, her contributions to the field of pharmaceutical technology are noteworthy. Hui An works alongside her colleagues Yan Zhang and Miaomiao Wei, collaborating on innovative projects aimed at developing new therapeutic compounds.

Latest Patent Applications: Hui An has recently filed patent applications for two significant compounds. The first application is for a heterocyclic compound having anti-tumor activity and its use. This class of compounds features a tri-heterocyclic structure, which represents a novel approach in the development of SOS1 inhibitor drugs. In vitro studies indicate that these compounds exhibit a strong inhibition effect on SOS1, making them potential candidates for preventing and treating SOS1-mediated diseases. Additionally, these compounds show significant inhibitory activity on NCI-H358 cell proliferation, and a specific synthesis method is provided that is simple and beneficial for large-scale production.

The second application is for a compound that acts as a cyclin-dependent kinase 9 (CDK9) inhibitor. This compound demonstrates excellent activity in treating hyperproliferative diseases. Experimental research has shown that it effectively inhibits cell proliferation in vitro and suppresses tumors in vivo, showcasing good selectivity, low toxicity, and minimal side effects. This positions the compound as a promising candidate for novel anti-tumor drugs.

Conclusion: Hui An's innovative work in pharmaceutical technology, particularly her latest patent applications, highlights her potential impact on the field. Her research efforts contribute to the development of new therapeutic options for treating serious diseases.